MedTrace Logo

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

NCT04583501 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-08-13

No results posted yet for this study

Summary

The goal of this study is to examine the mechanism of action of omalizumab in ex vivo tissue culture of whole human nasal polyps from patients with chronic rhino sinusitis with nasal polyposis (CRSwNP), such that specific molecular markers of inflammation can be identified.

Conditions

Interventions

BIOLOGICAL

Omalizumab

Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.

Sponsors & Collaborators

Principal Investigators

  • Jean Kim, MD PhD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2024-07-12
Completion
2024-07-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04583501 on ClinicalTrials.gov